Ciprofloxacin during pregnancy

Posted: leopoldl Date of post: 06-Feb-2019
<strong>Ciprofloxacin</strong> cautions, contraindications, <strong>pregnancy</strong>, breastfeeding

Ciprofloxacin cautions, contraindications, pregnancy, breastfeeding

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use. CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment. Animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. Levels reported were 57% (at 2 to 4 hours postdose) to 1000% (at 10 to 12 hours postdose) of that found in maternal serum. In rabbits, gastrointestinal toxicity was observed with oral doses and resulted in maternal weight loss and increased incidence of abortion, intrauterine deaths, and fetal retardation (but no teratogenicity); no maternal toxicity (and no embryotoxicity or teratogenicity) observed with IV doses. An expert review by the Teratogen Information System concluded that substantial teratogenic risk is unlikely using therapeutic doses; data insufficient to state there is no risk. In a controlled prospective observational study, 200 women exposed to fluoroquinolones (52.5% to ciprofloxacin and 68% during the first trimester) during gestation were followed. No increased risk of major malformations associated with in utero fluoroquinolone exposure during embryogenesis. Major congenital malformation rates were 2.2% for the fluoroquinolone group and 2.6% for the control group; background rate of major malformations was 1% to 5%. Rates of spontaneous abortions, prematurity, and low birth weight were not different between the groups; no clinically significant musculoskeletal dysfunctions observed in infants (up to 1 year of age) exposed to this drug. A prospective follow-up study by the European Network of Teratology Information Services reported on 549 pregnancies with fluoroquinolone exposure; 93% were first-trimester exposures and included all 70 exposures to ciprofloxacin.

<b>Ciprofloxacin</b> Use by Pregnant and Lactating Women - FDA
Ciprofloxacin Use by Pregnant and Lactating Women - FDA

While there are no controlled studies of ciprofloxacin use in pregnant women to show safety, an expert review of published data on experiences. What should I Know Regarding Pregnancy, Nursing and Administering Cipro to. tendinitis, tendon rupture during or post treatment, and potential arthropathy.

Ciprofloxacin during pregnancy
Rating 4,5 stars - 845 reviews